Peak Financial Advisors
DNTH icon

Peak Financial Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Peak Financial Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.73M Sell
19,636
-53
-0.3% -$5.5K 0.75% 40
2026
Q2 		$1.92M Buy
+19,689
New +$1.72M 0.79% 37

Other funds holding DNTH

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Peak Financial Advisors's DNTH Position: Q3 2026 in Review

Peak Financial Advisors reduced its Dianthus Therapeutics (DNTH) stake by 0.27% in Q3 2026, selling an estimated $5.5K and leaving 19,636 shares worth $1.73M. The position accounts for 0.75% of the portfolio, ranked #40.

Peak Financial Advisors first reported a position in DNTH in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.92M in Q2 2026. 42 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Peak Financial Advisors held 19,636 shares of Dianthus Therapeutics worth $1.73M as of Q3 2026.
  • Peak Financial Advisors sold 53 Dianthus Therapeutics shares in Q3 2026, an estimated $5.5K.
  • Dianthus Therapeutics made up 0.75% of Peak Financial Advisors's portfolio in Q3 2026, its #40 holding.
  • Peak Financial Advisors first reported a position in Dianthus Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Peak Financial Advisors's Dianthus Therapeutics position peaked at $1.92M in Q2 2026.
  • 42 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Peak Financial Advisors's 13F filing for Q3 2026, filed 28 Oct 2026.